164535-25-5

Upstream product

• 104-85-8 para-methylbenzonitrile 
• 24994-04-5 5-(4-methylphenyl)-2H-tetrazole 

Downstream Products

• 164535-28-8 2-butyl-1-<<4-<1-(triphenylmethyl)tetrazol-5-yl>phenyl>methyl>-5-formylimidazole 
• 1274939-79-5 Br^(1-)*C₅₃H₄₅N₆O₂⁽¹⁺⁾ 
• 171515-73-4 1-Butyl-5-[1-{2-butyl-3-[4-(2-trityl-2H-tetrazol-5-yl)-benzyl]-3H-imidazol-4-yl}-meth-(E)-ylidene]-imidazolidine-2,4-dione 
• 171515-72-3 1-Butyl-5-[1-{2-butyl-3-[4-(2-trityl-2H-tetrazol-5-yl)-benzyl]-3H-imidazol-4-yl}-meth-(Z)-ylidene]-imidazolidine-2,4-dione 

Relevant academic research and scientific papers

Towards non-peptide ANG II AT1 receptor antagonists based on urocanic acid: Rational design, synthesis and biological evaluation

A series of o-, m- and p-benzyl tetrazole derivatives 11a-c has been designed, synthesized and evaluated as potential Angiotensin II AT1 receptor antagonists, based on urocanic acid. Compound 11b with tetrazole moiety at the m-position showed moderate, however, higher activity compared to the o- and p-counterpart analogues. Molecular modelling techniques were performed in order to extract their putative bioactive conformations and explore their binding modes.

IMIDAZOLE WITH ANGIOTENSIN II ANTAGONIST PROPERTIES

This invention relates to novel substituted imidazole and triazole derivatives which antagonize the binding of angiotensin II to its receptors. The compounds are useful in the treatment of hypertension, heart failure, glaucoma, and hyperaldosteronism. Methods of making the compounds, novel intermediates useful in the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of using them are also covered.